Oregon Therapeutics
Paris
About Oregon Therapeutics
Oregon Therapeutics is developing XCE853 : disruptive targeted therapy “first in class” and “best in class” in oncology. XCE853 is based on an innovative and unique mechanism of action: inhibition of protein disulfide isomerase. OregonTherapeutics first objective is to bring XCE853 into the clinical phase for the treatment of cancer within 2 years. Based on the scientific rationale to exploit the metabolic vulnerability of some cancers, the two priority indications are ovarian cancer and advanced pancreatic cancer.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Last round: Series Unknown (Jan 2015)
- Website: oregon-therapeutics.com
- Phone: +33 0 6 01 03 43 43
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/oregon-therapeutics-2437976 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.